A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S9.2-10. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957 67. 9.2.1. Heart Failure With Reduced Ejection Fraction S9.2.1-1. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83:52 60. S9.2.1-2. Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest. 1998;113:867 9. S9.2.1-3. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of con- gestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol. 1999;84:611 2; A9. S9.2.1-4. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of con- gestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137:631 9. S9.2.1-5. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251 9. S9.2.1-6. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart fail- ure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948 55. S9.2.1-7. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282 93. S9.2.1-8. 